Health Consequences Among COVID-19 Convalescent Patients 30 Months Post-Infection in China

The health consequences among COVID-19 convalescent patients 30 months post-infection were described and the potential risk factors were determined. In August 2022 we recruited 217 COVID-19 convalescent patients who had been diagnosed with COVID-19 in February 2020. These convalescent patients were residents of multiple districts in Wuhan, China. All convalescent patients completed a detailed questionnaire, laboratory testing, a 6-min walk test, a Borg dyspnea scale assessment, lung function testing, and had a chest CT. The potential risk factors for health consequences among COVID-19 convalescent patients 30 months post-infection were identified using a multivariate logistic regression model. The majority of convalescent patients were in good overall health and returned to work 30 months post-infection; however, 62.2% of the convalescent patients had long COVID symptoms. The most common symptoms were chest pain, fatigue, and dizziness or headaches. The convalescent patients with severe symptoms had a significantly higher proportion of depression disorder ( P = 0.044) and lower health-related quality of life ( P = 0.034) compared to the convalescent patients with mild symptoms. Compared to convalescent patients who were not vaccinated, convalescent patients who received three vaccines had significantly less fatigue, lower anxiety and depression scores, and had a better health-related quality of life (all P < 0.05). Older age was associated with a higher risk of long COVID (OR = 1.52, 95% CI = 1.16–2.02) and chest CT abnormalities (OR = 1.75, 95% CI = 1.33–2.36). Female gender was associated with a higher risk of anxiety (OR = 3.20, 95% CI = 1.24–9.16) and depression disorders (OR = 2.49, 95% CI = 1.11–5.92). Exercise was associated with a lower risk of anxiety (OR = 0.41, 95% CI = 0.18–0.93). Notably, vaccination protected convalescent patients from developing long COVID symptoms (OR = 0.18, 95% CI = 0.06–0.50), anxiety disorders (OR = 0.22, 95% CI = 0.07–0.71), and depression disorders (OR = 0.33, 95% CI = 0.12–0.92). The majority of COVID-19 convalescent patients were in good overall health 30 months post-infection and returned to work. More attention should be paid to convalescent patients who are older, female, physically inactive, and not vaccinated

The generation of glioma organoids and the comparison of two culture methods

Abstract Background The intra‐ and inter‐tumoral heterogeneity of gliomas and the complex tumor microenvironment make accurate treatment of gliomas challenging. At present, research on gliomas mainly relies on cell lines, stem cell tumor spheres, and xenotransplantation models. The similarity between traditional tumor models and patients with glioma is very low. Aims In this study, we aimed to address the limitations of traditional tumor models by generating patient‐derived glioma organoids using two methods that summarized the cell diversity, histological features, gene expression, and mutant profiles of their respective parent tumors and assess the feasibility of organoids for personalized treatment. Materials and Methods We compared the organoids generated using two methods through growth analysis, immunohistological analysis, genetic testing, and the establishment of xenograft models. Results Both types of organoids exhibited rapid infiltration when transplanted into the brains of adult immunodeficient mice. However, organoids formed using the microtumor method demonstrated more similar cellular characteristics and tissue structures to the parent tumors. Furthermore, the microtumor method allowed for faster culture times and more convenient operational procedures compared to the Matrigel method. Discussion Patient‐derived glioma organoids, especially those generated through the microtumor method, present a promising avenue for personalized treatment strategies. Their capacity to faithfully mimic the cellular and molecular characteristics of gliomas provides a valuable platform for elucidating tumor biology and evaluating therapeutic modalities. Conclusion The success rates of the Matrigel and microtumor methods were 45.5% and 60.5%, respectively. The microtumor method had a higher success rate, shorter establishment time, more convenient passage and cryopreservation methods, better simulation of the cellular and histological characteristics of the parent tumor, and a high genetic guarantee